Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJM716 + BYL719 versus taxane or irinotecan in previously treated esophageal squamous cell carcinoma
2012-005624-15Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elgemtumab and alpelisib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Novartis. Primary endpoint: Dose-limiting toxicities (DLTs) incidence. Started May 2013; status: completed.
02
Drugs
elgemtumabalpelisib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2012-005624-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005624-15.